Tumor cells were seen to have strong membranous IGF1R immunostaining (m-IGF1R 2+) in 7 (5.0%) cases and weak membranous IGF1R immunostaining (m-IGF1R 1+) in 9 (6.5%) cases. This evidence concerns the gene IGF1R and neoplasm.